Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management.
نویسنده
چکیده
After a stroke or transient ischaemic attack (TIA) there is a high risk of stroke, particularly in the early days and weeks, and of other serious vascular events. Several preventive medical treatments can reduce these risks; starting them as early as possible will maximise the absolute risk reduction, as long as the diagnosis is secure, there is no known or suspected net harm from treatment, and they are acceptable to the patient. Medical treatments with clear evidence of benefit include: lowering blood pressure after all types of stroke or TIA; lowering blood cholesterol with a statin after ischaemic stroke or TIA; antiplatelet treatment after ischaemic stroke or TIA; and warfarin instead of antiplatelet treatment in patients with ischaemic stroke or TIA who have atrial fibrillation and no contraindications to anticoagulation. Lifestyle changes (for example, stopping smoking, reducing excess alcohol intake, adopting a healthy diet) and careful management of diabetes are also important.
منابع مشابه
Night time versus daytime transient ischaemic attack and ischaemic stroke: a prospective study of 110 patients.
OBJECTIVE Ischaemic stroke occurs only in 20%-40% of patients at night. The aim of the study was to compare sleep and stroke characteristics of patients with and without night time onset of acute ischaemic cerebrovascular events. METHODS A consecutive series of 110 patients with transient ischaemic attack (n=45) or acute ischaemic stroke (n=65) was studied prospectively by means of a standard...
متن کاملAntiplatelet drugs.
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is recommended as the first-line antiplatelet drug. Cl...
متن کاملUpdate of secondary stroke prevention.
Secondary prevention aims at preventing a stroke after a transient ischaemic attack (TIA) or a recurrent stroke after a first stroke. About 80–85% of patients survive a first ischaemic stroke [1,2]. Of those, between 8 and 15% suffer a recurrent stroke in the first year. The risk of stroke recurrence is highest in the first few weeks and declines over time [3–5]. The risk of recurrence depends ...
متن کاملAntiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis
OBJECTIVE To examine the comparative efficacy and safety of different antiplatelet regimens in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack. DESIGN Systematic review and network meta-analysis. DATA SOURCES As on 31 March 2015, all randomised controlled trials that investigated the effects of antiplatelet agents in the long-term (≥ 3 months) secondary ...
متن کاملVAST: Vertebral Artery Stenting Trial. Protocol for a randomised safety and feasibility trial
BACKGROUND Twenty to 30 percent of all transient ischaemic attacks and ischaemic strokes involve tissue supplied by the vertebrobasilar circulation. Atherosclerotic stenosis >/= 50% in the vertebral artery accounts for vertebrobasilar stroke in at least one third of the patients. The risk of recurrent vascular events in patients with vertebral stenosis is uncertain and revascularisation of vert...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Practical neurology
دوره 8 3 شماره
صفحات -
تاریخ انتشار 2008